| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5665772 | NOVARTIS PHARM | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Sep, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6004973 | NOVARTIS PHARM | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jul, 2016
(7 years ago) | |
|
US6004973 (Pediatric) | NOVARTIS PHARM | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jan, 2017
(7 years ago) | |
| US7297703 | NOVARTIS PHARM | Macrolides |
Dec, 2019
(4 years ago) | |
|
US5665772 (Pediatric) | NOVARTIS PHARM | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Mar, 2020
(4 years ago) | |
|
US7297703 (Pediatric) | NOVARTIS PHARM | Macrolides |
Jun, 2020
(3 years ago) | |
| US8778962 | NOVARTIS PHARM | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(2 years ago) | |
|
US8778962 (Pediatric) | NOVARTIS PHARM | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(1 year, 8 months ago) | |
| US8617598 | NOVARTIS PHARM | Pharmaceutical compositions comprising colloidal silicon dioxide |
Sep, 2022
(1 year, 6 months ago) | |
|
US8617598 (Pediatric) | NOVARTIS PHARM | Pharmaceutical compositions comprising colloidal silicon dioxide |
Mar, 2023
(1 year, 1 month ago) | |
Afinitor Disperz is owned by Novartis Pharm.
Afinitor Disperz contains Everolimus.
Afinitor Disperz has a total of 10 drug patents out of which 10 drug patents have expired.
Expired drug patents of Afinitor Disperz are:
- US6004973
- US6004973*PED
- US7297703
- US5665772*PED
- US7297703*PED
- US8778962
- US8778962*PED
- US8617598
- US8617598*PED
- US5665772
Afinitor Disperz was authorised for market use on 29 August, 2012.
Afinitor Disperz is available in tablet, for suspension;oral dosage forms.
Afinitor Disperz can be used as adjunctive treatment of patients with tsc-associated partial-onset seizures.
Drug patent challenges can be filed against Afinitor Disperz from 29 April, 2017.
The generics of Afinitor Disperz are possible to be released after 10 April, 2025.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-169) | Apr 10, 2025 |
| New Indication(I-773) | Apr 10, 2021 |
| Pediatric Exclusivity(PED) | Apr 29, 2014 |
| Orphan Drug Exclusivity(ODE) | Oct 29, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 30, 2014 |
| New Indication(I-630) | Oct 29, 2013 |
Drugs and Companies using EVEROLIMUS ingredient
NCE-1 date: 29 April, 2017
Market Authorisation Date: 29 August, 2012
Treatment: Adjunctive treatment of patients with tsc-associated partial-onset seizures
Dosage: TABLET, FOR SUSPENSION;ORAL
AFINITOR DISPERZ family patents
